It's going to be interesting to see how it turns out. Genentech has already made a good return on lucentis, its recent run rate is >$800M. If it turns out the two drugs are similar in efficacy, I won't feel bad for dna. If lucentis is truly better then it will be a nice vindication for dna.
As far as powering, if genentech is saying you need a massive trial to detect differences that doesn't indicate they expect a large one. (would be nice to know how big a trial is planned so we can compare it to regn vegf trap vs lucentis for example).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.